BIOMAT Database Logo BIOMAT Database Logo

[Comparative evaluation of the therapeutic effect of oxyferriscorbone in peptic ulcer]. 1985

A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010208 Papaverine An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. Cerespan,Papaverine Hydrochloride,Pavabid,Pavatym,Hydrochloride, Papaverine
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D010437 Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). Gastroduodenal Ulcer,Marginal Ulcer,Gastroduodenal Ulcers,Marginal Ulcers,Peptic Ulcers,Ulcer, Gastroduodenal,Ulcer, Marginal,Ulcer, Peptic,Ulcers, Gastroduodenal,Ulcers, Marginal,Ulcers, Peptic
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[The efficacy of oxyferriscorbone in peptic ulcer].
October 1990, Vrachebnoe delo,
A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[Use of sodium oxyferriscorbone, lidocaine and therapeutic endoscopy in peptic ulcer].
September 1984, Vrachebnoe delo,
A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[The place of sodium oxyferriscorbone in the treatment of peptic ulcer].
January 1951, Paris medical,
A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[Evaluation of the therapeutic effect of hyperbaric oxygenation and anginin in peptic ulcer].
January 1989, Terapevticheskii arkhiv,
A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[Comparative evaluation of hexonium therapy in peptic ulcer].
May 1965, Vrachebnoe delo,
A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[THERAPEUTIC EVALUATION OF AMBUTONIUM BROMIDE IN PEPTIC ULCER].
September 1963, Polski tygodnik lekarski (Warsaw, Poland : 1960),
A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[Oxyferriscorbone in the therapy of ulcer].
June 1970, Giornale di clinica medica,
A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[Evaluation of the therapeutic effect produced by methylthionine-sulfonium chloride in peptic ulcer].
August 1972, Sovetskaia meditsina,
A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[Therapeutic effect of isobarin in gastric peptic ulcer].
April 1974, Klinicheskaia meditsina,
A M Spivak, and V K Reĭngardt, and T M Galetskaia, and N A Liashko, and E V Litinskaia
[Comparative evaluation of methods of treating peptic ulcer].
September 1984, Khirurgiia,
Copied contents to your clipboard!